Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Bengaluru-based biopharmaceutical firm Biocon on Monday launched a qualified institutions placement (QIP) to raise Rs 4,500 crore. As part of the offering, the firm will issue up to 139 million new shares — 11.6 per cent of its current outstanding equity base. The floor price for the QIP has been set at Rs 323.2.

Shares of Biocon last closed at Rs 357.3, valuing the firm at Rs 42,900 crore. The issuance price will be finalised on Thursday, while trading in the new shares will commence from Tuesday.

This comes after the company’s board had approved the raising of funds by way of QIPs for an aggregate amount of up to Rs 4,500 crore on 23 April. The move received shareholder approval on 4 June through postal ballot.

Biocon will use the QIP proceeds to purchase outstanding optionally convertible debentures issued by subsidiary Biocon Biologics. It will also use the proceeds to repay outstanding debt and for general corporate purposes.

In an earnings call for Q4FY25, Kedar Upadhye, Chief Financial Officer (CFO) of Biocon Biologics, stated that the company had a net debt of US$1.2 billion, excluding structured instruments.

In the same call, Biocon Chief Executive Officer (CEO) and Managing Director Siddharth Mittal added that the first tranche was expected to be completed by mid-June.

“The proceeds of the fund will primarily be used to meet financial obligations towards the commitments and the put options from the structured debt that we had from the investments in Biocon Biologics,” he said.

In an interview last month, Biocon Executive Chairperson Kiran Mazumdar-Shaw had also stated that their goal was to complete the fundraising within three to four months.

BofA Securities, Kotak Mahindra and Goldman Sachs are the investment bankers handling the share sale, according to the company’s regulatory filing.

The company’s announcement came after market hours. On Monday, Biocon’s shares went up marginally by 0.52 per cent, closing the day’s trade at Rs 357.30.

Related Posts

  • Pharma
  • July 24, 2025
  • 97 views
Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

  • Pharma
  • July 22, 2025
  • 181 views
DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra